Skip to main content
. 2013 Apr 9;14(1):54–62. doi: 10.1038/tpj.2013.14

Figure 1.

Figure 1

Study design and analysis. Growth hormone (GH) was administered daily during 1 month in two different treatment-naïve short pre-pubertal groups at a standard dose: GH deficiency (GHD) or Turner syndrome (TS). Analyses were performed to address specific questions in both GHD and TS. (1) How do serum insulin-like growth factor-I (IGF-I) levels change (ΔIGF-I) over 1 month of recombinant human (r-h)GH therapy (comparing IGF-I before first GH injection (W0) and at week 4 (W4))? (2) Are specific single-nucleotide polymorphisms (SNPs) from a candidate gene list associated with ΔIGF-I (analyzed in DNA extracted from peripheral blood nucleated cells (PBMC) at W0. (3) Which genes display a change in expression over 1 month of GH treatment (analyzed in mRNA from PBMC, W0 versus W4 (full genome))? (4) Does baseline gene expression correlate with 1 month ΔIGF-I (analyzed in mRNA at W0)? (5) Does baseline gene expression differ in lowest quartile of 1-month ΔIGF-I (analyzed in mRNA, comparing W0 Q1 ΔIGF-I with Q2+Q3+Q4 ΔIGF-I)?